Targeting Cancer Cell Dormancy.


Journal

Trends in pharmacological sciences
ISSN: 1873-3735
Titre abrégé: Trends Pharmacol Sci
Pays: England
ID NLM: 7906158

Informations de publication

Date de publication:
02 2019
Historique:
received: 31 07 2018
revised: 22 10 2018
accepted: 06 12 2018
pubmed: 8 1 2019
medline: 14 3 2019
entrez: 8 1 2019
Statut: ppublish

Résumé

Cancer cell dormancy is a process whereby cells enter reversible cell cycle arrest, termed quiescence. Quiescence is essential for cancer cells to acquire additional mutations, to survive in a new environment and initiate metastasis, to become resistant to cancer therapy, and to evade immune destruction. Thus, dormant cancer cells are considered to be responsible for cancer progression. As we start to understand the mechanisms that enable quiescence, we can begin to develop pharmacological strategies to target dormant cancer cells. Herein, we summarize the major molecular mechanisms underlying the dormancy of disseminated tumor cells and drug-tolerant persister cells. We then analyze the current pharmacological strategies aimed (i) to keep cancer cells in the harmless dormant state, (ii) to reactivate dormant cells to increase their susceptibility to anti-proliferative drugs, and (iii) to eradicate dormant cancer cells.

Identifiants

pubmed: 30612715
pii: S0165-6147(18)30229-3
doi: 10.1016/j.tips.2018.12.004
pii:
doi:

Substances chimiques

Antineoplastic Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

128-141

Informations de copyright

Copyright © 2018 Elsevier Ltd. All rights reserved.

Auteurs

Ariadna Recasens (A)

Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, NSW 2006, Australia.

Lenka Munoz (L)

Faculty of Medicine and Health, Charles Perkins Centre, The University of Sydney, NSW 2006, Australia. Electronic address: lenka.munoz@sydney.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH